Last reviewed 2026-04-19 · How we verify

DODECLONIUM BROMIDE

Phase 2 active Small molecule

DODECLONIUM BROMIDE is a drug. It is currently in Phase 2 development.

Unfortunately, there is not enough information available to provide a one-sentence summary of how dodeclonium bromide works.

Dodeclonium bromide is a small molecule compound with unknown target and drug class. Its original development is unclear, and its current status is also unknown. There is no information available on its approved indications, half-life, bioavailability, generic manufacturers, or off-patent status. As a result, its commercial status and key safety considerations cannot be determined. Further research is needed to understand this compound's properties and potential applications.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DODECLONIUM BROMIDE
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Due to the lack of information, it is not possible to explain how dodeclonium bromide works in a way that a patient could understand.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DODECLONIUM BROMIDE CI brief — competitive landscape report
DODECLONIUM BROMIDE updates RSS · CI watch RSS

Frequently asked questions about DODECLONIUM BROMIDE

What is DODECLONIUM BROMIDE?

DODECLONIUM BROMIDE is a Small molecule drug.

How does DODECLONIUM BROMIDE work?

Unfortunately, there is not enough information available to provide a one-sentence summary of how dodeclonium bromide works.

What development phase is DODECLONIUM BROMIDE in?

DODECLONIUM BROMIDE is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing